Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for obsessive-compulsive disorder symptoms
IRCT20140120016280N4Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Memantine with Placebo (2 arms). Primary endpoints: Symptoms (obsessions and compulsions) severity and Response rate to memantine treatment. Started Sep 2020; status: completed.
02
Drugs
memantine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20140120016280N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140120016280N4.